ATAGI has provided updated advice regarding COVID-19 booster doses for those aged 12-15 years.
A single booster dose of Comirnaty (Pfizer) is now recommended for the following select groups:
- those who are severely immunocompromised
- those who have a disability with significant or complex health needs
- those who have complex and/or multiple health conditions that increase the risk of severe COVID-19.
Booster doses can be administered ≥ 3 months after the completion of the primary course, or ≥ 3 months after COVID-19 infection (whichever is later).
There is currently insufficient evidence to support expanding this booster dose recommendation to other groups of adolescents aged 12-15 years, however this advice may change in the future as more evidence emerges.
To read the advice in full please follow the link below.
ATAGI recommendations on first booster dose in adolescents aged 12-15 years